Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PRLDthis companyPrelude Therapeutics Incorporated	$3.84	-2.25×	3.25×	18.38×	-1.48×	-2.4%	85.9%	-861.3%	-819.6%	-145.0%	-114.8%	-25.3%	0.26×	0.18×	0×	1.99×	0.0%	4	-3.06	2	C
AVTXAvalo Therapeutics, Inc.	$7.02	-3.11×	2.93×	4,125.96×	-2.96×	-86.5%	100.0%	-123601.7%	-132642.4%	-94.2%	-70.2%	-21.1%	0.03×	0.17×	0×	8.14×	0.0%	2	4.43	2	B-
CRBUCaribou Biosciences, Inc.	$0.46	-1×	1.22×	13.31×	-1.13×	-908.6%	67.3%	-1220.5%	-1327.4%	-121.2%	-89.8%	-75.7%	0.22×	-0.1×	0×	5.71×	0.0%	3	-7.25	2	C
ENTAEnanta Pharmaceuticals, Inc.	$11.49	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
FHTXFoghorn Therapeutics Inc.	$2.01	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
IMRXImmuneering Corporation	$3.60	-5.18×	1.33×	0×	-2.96×	-19.7%	0.0%	0.0%	0.0%	-25.6%	-26.7%	-15.7%	0.02×	2.24×	0×	17.5×	0.0%	0	6.81	2	B-
Peer median	—	-3.12×	1.33×	11×	-2.96×	-669.1%	89.2%	-265.6%	-240.3%	-94.2%	-58.9%	-21.1%	0.03×	0.17×	0×	5.71×	0.0%	3	-0.92	2	—